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QSARAbstract A series of 4-(1-aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted
benzenesulfonamide derivatives (1–20) was synthesized and evaluated for its in vitro antimicrobial
and anticancer activities. Antimicrobial results indicated that compounds N-(4-(1-benzoyl-5-chloro-
2-oxoindolin-3-ylideneamino) phenylsulfonyl)-4-isopropoxy benzamide (9) and N-(4-(5-chloro-1-
(2-chlorobenzoyl)-2-oxoindolin-3-ylideneamino) phenylsulfonyl)-4-isopropoxybenzamide (19) were
found to be the most effective ones. The anticancer results indicated that almost all the synthesized
compounds were more active than the standard drug carboplatin but less active than the standard
drug 5-ﬂuorouracil (5-FU) against both the cell lines (HCT116 and RAW 264.7). 4-(1-Benzoyl-5-
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Scheme 1 Synthetic scheme of the
fonamide derivatives (1–20).
4-(1-Aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted benzene sulfonamides 437chloro-2-oxoindolin-3-ylideneamino)-N-(pyrimidin-2-yl) benzenesulfonamide (3) was found to be
most potent and exhibited selectivity toward HCT 116. QSAR studies indicated that antimicrobial
activity of isatin derivatives against different microbial strains was governed by lipophilic parame-
ter, log P and topological parameters valance zero and third order molecular connectivity indices
(0vv and 3vv).
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The prevalence of multi-drug resistant microbial infections in
the past few decades has become a serious health care problem.
Prudent use of antibiotics and development of novel antimi-
crobial agents seem to be the common strategies and action
plans taken to combat this challenge. Consequently, the search
for new antimicrobial agents will always remain an important
task for medicinal chemists (Metwally et al., 2006).
Cancer has become the second cause of mortality in the
world and the development of potent and speciﬁc anticancer
agents is urgently required due to problems associated with
the existing drugs which include toxicity as well as resistance
(Kamal et al., 2010). This undoubtedly underscores the need
of developing novel anticancer agents.
Isatin is a natural product found in a number of plants,
including those of the genus Isatis. It is an endogenous com-
pound isolated in 1988 that has been reported to possess a
wide range of central nervous system activities. Several com-
pounds containing an isatin moiety have also been docu-
mented to possess antimicrobial (Karthikeyan et al., 2010),
anticonvulsant (Siddiqui et al., 2011), anti-inﬂammatory
(Nirmal et al., 2010), anticancer (Liang et al., 2008) and
anti-HIV (Banerjee et al., 2010) activities.
Aminopeptidase N (APN/CD13) is a zinc-dependent metal-
loprotease ectoenzyme widely expressed on hematopoietic cells
of myeloid origin and non-hematopoietic cells and tissues,
such as brain cells, ﬁbroblasts, and epithelial cells of the kid-
ney, liver, and intestine. Over-expression of APN is often asso-
ciated with many diseases, such as cancer, viral infection and
inﬂammation. In the process of tumorigenesis, it plays a cru-
cial role in tumor invasion, metastasis and angiogenesis. Since
the ﬁrst marketed anti-APN drug Bestatin that was launched
in 1976, many APN inhibitors (APNIs) which includeH2N
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synthesis of 4-(1-aryl-5-chloro-2probestin, lapstatin and AHPA-Val have been reported. In-
dole-2,3-dione (isatin) derivatives such as APNIs have also
been described. Preliminary results demonstrated that most
of the isatin derivatives exhibited better inhibition than besta-
tin (Jin et al., 2013).
Recently, it has been reported that 5,7-dibromoisatin is sig-
niﬁcantly more potent in vitro as a cytotoxin than the parent
molecule (isatin) against U937 (human monocyte-like histio-
cytic lymphoma) cells (Matesic et al., 2008). The substitution
of bromo and chloro groups at the C-5 and C-7 positions of
isatin exhibited potent anticancer activity. These isatin analogs
were also potent against a wide range of other human cancer
cell lines, including MDA-MB-231 metastatic breast adenocar-
cinoma cells. Several isatin-b-thiosemicarbazones have dis-
played activity against a parental HeLa-derived cervical
cancer cell line (KB-3-1) expressing the efﬂux pump multidrug
resistance (MDR). The anticancer activity of a number of isat-
in derivatives conjugated to a cell targeting moiety via a spacer
group has also been described (Penthala et al., 2010).
On the other hand, sulfonamides have a variety of biologi-
cal activity which includes antibacterial, insulin releasing, car-
bonic anhydrase inhibition, anti-inﬂammation, and antitumor
properties (Rohini et al., 2011). These agents block important
metabolic steps of the microorganisms e.g. sulfonamides.
Moreover, due to their metabolic inhibitory action, sulfon-
amide-based heterocycles (Selvam et al., 2006) represent an
attractive target of contemporary organic synthesis. These ear-
lier ﬁndings encouraged us to explore the synthesis of sulfona-
mides using isatin moiety and to examine their antibacterial,
antifungal and anticancer properties. There are accumulating
lines of evidence that hybridization of two or more different
bioactive molecules with complementary pharmacophoric
functions or with different mechanisms of action often renders
synergistic effects (Solomon et al., 2009).S
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-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted benzenesul-
Table 1 Physicochemical characteristics and anticancer activity of the synthesized isatin derivatives.
Comp. M. formula M. Wt. Rf value
* IC50 in lM
HCT116 Raw 264.7
1 C25H17ClN4O5S 520.94 0.62 109.42 57.59
2 C23H16ClN3O5S 481.91 0.78 124.50 87.15
3 C25H16ClN5O4S 517.94 0.84 17.38 54.06
4 C26H18ClN5O4S 531.97 0.76 24.44 45.12
5 C24H15ClN4O4S2 522.98 0.68 99.43 15.30
6 C27H20ClN5O6S 578.00 0.74 112.46 25.95
7 C26H18ClN5O5S 547.97 0.78 80.30 9.12
8 C26H17ClN4O4S 516.96 0.80 96.72 9.67
9 C31H24ClN3O6S 602.06 0.80 101.32 13.29
10 C22H16ClN5O4S 481.91 0.72 124.50 16.60
11 C25H16Cl2N4O5S 555.39 0.78 90.03 10.80
12 C23H15Cl2N3O5S 516.35 0.66 38.73 11.62
13 C25H15Cl2N5O4S 552.39 0.82 72.41 18.10
14 C26H17Cl2N5O4S 566.42 0.70 61.79 8.83
15 C24H14Cl2N4O4S2 557.43 0.66 39.47 8.97
16 C27H19Cl2N5O6S 612.44 0.70 42.45 8.16
17 C26H17Cl2N5O5S 582.41 0.80 85.85 8.59
18 C26H16Cl2N4O5S 551.40 0.64 97.93 10.88
19 C31H23Cl2N3O6S 636.50 0.62 83.27 11.00
20 C22H15Cl2N5O4S 516.36 0.78 133.63 13.56
Carboplatin >100 >100
5-Flourouracil 4.6 4.6
* TLC mobile phase: chloroform: methanol (9:1).
438 M. Kumar et al.QSARmodels are highly effective in describing the structural
basis of biological activity. The success of QSAR approach can
be explained by the insight offered into the structural determina-
tion of chemical properties and the possibility to estimate theTable 2 Antimicrobial activity (lM/ml) of synthesized isatin
derivatives.
Comp. pMICsa pMICbs pMICec pMICca pMICan
1a 1.62 1.62 1.62 2.22 1.92
2 1.89 1.59 1.59 1.59 1.89
3a 1.92 1.92 1.62 2.22 1.92
4 1.93 1.93 1.63 2.23 1.93
5 1.62 1.92 1.92 2.22 1.92
6 1.67 1.67 1.97 2.27 1.97
7a 1.94 1.94 1.94 2.24 1.94
8 1.62 1.92 1.92 1.62 1.92
9 1.98 1.98 1.98 1.68 1.98
10 1.59 1.59 1.59 1.59 1.89
11a 1.65 1.65 1.95 1.65 1.95
12 1.92 1.62 1.92 2.22 1.92
13 1.65 1.95 1.95 1.65 1.95
14 1.96 1.96 1.96 1.96 1.96
15 1.95 1.95 1.95 1.95 1.95
16a 1.69 1.69 1.99 1.99 1.99
17a 1.67 1.97 1.97 1.97 1.97
18 1.95 1.95 1.95 2.25 1.95
19 2.01 2.01 2.01 2.31 2.01
20 1.92 1.62 1.92 2.22 1.92
SD 0.16 0.16 0.15 0.27 0.03
Std. 2.61* 2.61* 2.61* 2.64** 2.64**
SD – standard deviation.
* Norﬂoxacin.
** Fluconazole.
a Outliers.properties of new chemical compounds without the need to syn-
thesize and test them (Sawant et al., 2013).
Prompted by the above facts and in continuation of our re-
search efforts in the ﬁeld of synthesis, antimicrobial, anticancer
evaluation and QSAR studies (Sharma et al., 2012; Kumar
et al., 2013; Sigraha et al., 2012), we hereby report synthesis,
antimicrobial, anticancer evaluation and QSAR studies of 4-
(1-aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-
substituted benzene sulfonamides.
2. Results and discussion
2.1. Chemistry
The synthesis of 4-(1-aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-
ylideneamino)-N-substituted benzene sulfonamide derivatives
(1–20) was accomplished (Scheme 1). The physicochemical
characteristics of the synthesized compounds are presented in
Table 1.
The synthesized compounds were characterized by IR and
1H NMR spectroscopy and the results are in accordance with
the assigned molecular structures. IR stretching band ranging
from 1688 to 1681 cm1 (C = O str., Ar–C = O) conﬁrmed
the acylation of isatin. IR stretching band at 1656–
1650 cm1 (C = N str.) conﬁrmed the formation of a Schiff
base. Further, peak of NH in plane bending at 1516–
1491 cm1, O = S = O str. at 1186–1142 cm1 conﬁrmed the
presence of sulfonamide moiety in the synthesized compounds.
In the 1H NMR spectra the signals of the respective protons
of the synthesized compounds were conﬁrmed based on their
chemical shifts, multiplicities and coupling constants. These
spectra showed a singlet at 4.01–4.76 ppm, which corresponds
to the SO2NH protons and multipletes at 6.55–8.74 ppm,
showed aromatic protons.
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Figure 1 Structure–activity relationship for antimicrobial and anticancer activity of synthesized isatin derivatives.
Table 3 Values of selected parameters used in QSAR studies of synthesized compounds.
Comp. log P MR 0vv 3vv k1 R Te LUMO HOMO l
1a 4.32 133.63 20.37 1.57 27.56 17.23 6426.55 1.48 9.38 8.75
2 3.17 121.62 18.85 1.49 26.07 15.67 5952.82 1.54 9.43 8.38
3a 4.11 133.31 20.07 1.44 27.56 17.33 6300.99 1.54 9.42 9.29
4 4.30 138.24 20.99 1.57 28.53 17.73 6456.81 1.54 9.40 9.14
5 4.70 133.32 20.33 1.54 26.60 16.83 6146.78 1.51 9.24 8.72
6 4.54 146.89 22.73 1.55 31.43 19.20 7252.72 1.62 9.45 8.86
7a 4.48 141.52 21.40 1.51 29.49 18.26 6776.44 1.39 9.32 2.92
8 4.49 134.88 20.20 1.46 27.56 17.33 6236.23 1.51 9.38 9.34
9 5.59 157.42 24.15 1.83 33.37 20.03 7407.09 1.52 9.36 7.68
10 3.24 122.47 18.52 1.46 26.07 15.67 5917.55 1.29 9.39 3.21
11a 4.84 138.44 21.49 1.73 28.53 17.64 6786.57 1.55 9.44 9.31
12 3.69 126.42 19.97 1.65 27.05 16.08 6312.81 1.56 9.47 8.92
13 4.63 138.11 21.19 1.60 28.53 17.74 6660.98 1.57 9.46 10.30
14 4.82 143.04 22.11 1.73 29.49 18.14 6816.80 1.55 9.45 10.38
15 5.22 138.13 21.45 1.70 27.56 17.24 6506.78 1.55 9.24 8.31
16a 5.06 151.70 23.85 1.71 32.40 19.61 7612.69 1.35 9.50 5.62
17a 5.00 146.33 22.52 1.67 30.46 18.67 7136.47 1.54 9.24 9.04
18 5.01 139.69 21.32 1.62 28.53 17.74 6596.22 1.52 9.38 9.52
19 6.10 162.23 25.26 1.99 34.34 20.44 7767.09 1.52 9.39 8.05
20 3.76 127.28 19.64 1.62 27.05 16.08 6277.56 1.30 9.39 2.82
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The antimicrobial activity of the synthesized compounds was
determined by tube dilution method (Cappucino and Sherman,
1999) and the results are given in Table 2. Compound 19 dem-
onstrated potent antibacterial activity against Staphylococcus
aureus (pMICsa = 2.01 lM). In the case of Bacillus subtilis
compounds 9 and 19 emerged as most effective antibacterial
agents with pMICbs values of 1.98 and 2.01 lM, respectively.
Compounds 9 and 19 (pMICec values 1.98 and 2.01 lM,
respectively) also emerged as the most active candidates among
the synthesized compounds against Gram-negative bacterium
Escherichia coli. In the case of antifungal activity against Can-
dida albicans, compound 19 emerged as the most active candi-
date among the synthesized compounds (pMICca values
2.31 lM) and against Aspergillus niger compounds, 9 and 19
(pMICan values 1.98 and 2.01 lM, respectively) emerged as
most active antifungal agents.
The antimicrobial results of the standard drugs, norﬂoxacin
and ﬂuconazole were almost similar against all the tested micro-
organisms. In the present study however, the standard drugs
were more potent than the synthesized compounds.In general, the results of MBC/MFC studies revealed that
the synthesized compounds were bacteriostatic and fungistatic
in action as their MFC and MBC values were (ranging from
>0.08 to >0.10 lM/ml) 3-fold higher than their MIC values
(a drug is considered to be bacteriosatic/fungistatic when its
MFC and MBC values are 3-fold higher than its MIC value
(Emami et al., 2004).
2.3. Anticancer activity
The anticancer activity (IC50) of the synthesized isatin deriva-
tives was determined against mouse leukemic monocyte mac-
rophage (RAW 264.7) and colon cancer (HCT116) cell lines
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay (Mosmann, 1983). The anticancer activ-
ity results are presented in Table 1. In general all the synthe-
sized compounds were more active than the standard drug
carboplastin (IC50 =>100 lM) but less active than the stan-
dard drug 5-FU (IC50 = 4.6 lM) against both the cell lines
(HCT116 and RAW 264.7). Compounds, 4-(1-Benzoyl-5-
chloro-2-oxoindolin-3-ylideneamino)-N-(pyrimidin-2-yl)benzene
sulfonamide (3) and 4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoin-
Table 4 Correlation matrix for the antifungal activity of synthesized compounds against A. niger.
log P MR 0vv k1 R Te LUMO HOMO l pMICan
log P 1.000 0.918 0.903 0.788 0.870 0.814 0.435 0.314 0.408 0.905
MR 1.000 0.989 0.962 0.991 0.959 0.439 0.033 0.346 0.963
0vv 1.000 0.966 0.976 0.979 0.470 0.002 0.348 0.980
k1 1.000 0.970 0.984 0.366 0.153 0.224 0.928
R 1.000 0.962 0.474 0.049 0.371 0.946
Te 1.000 0.426 0.153 0.271 0.970
LUMO 1.000 0.149 0.925 0.467
HOMO 1.000 0.149 0.036
l 1.000 0.356
pMICan 1.000
440 M. Kumar et al.dolin-3-ylideneamino)-N-(4,6-dimethoxypyrimidin-2-yl)benzene
sulfonamide (16) were found to be most potent with IC50
values of 17.38 lM against HCT116 and 8.16 lM against
RAW 264.7, respectively.
2.4. Structure–activity relationship
a. Results of the antimicrobial and anticancer screening
indicated that phenyl nucleus attached to benzenesulfon-
amide moiety increased the antimicrobial potential,
whereas its replacement with pyrimidine nucleus
improved the anticancer potential of the synthesized
isatin derivatives.Table 5 Correlation of antibacterial, antifungal and antimi-
crobial activity of synthesized compounds with calculated
molecular descriptors.
Descriptor pMICsa pMICbs pMICec pMICca pMICan
Cos E 0.183 0.642 0.345 0.062 0.325
log P 0.359 0.859 0.721 0.283 0.905
MR 0.365 0.701 0.617 0.266 0.963
0v 0.383 0.552 0.559 0.253 0.946
0vv 0.433 0.647 0.643 0.316 0.980
1v 0.300 0.653 0.582 0.238 0.946
1vv 0.388 0.760 0.659 0.290 0.950
2v 0.399 0.623 0.565 0.248 0.952
2vv 0.469 0.760 0.667 0.311 0.931
3v 0.623 0.197 0.354 0.255 0.742
3vv 0.706 0.505 0.564 0.326 0.832
j1 0.386 0.499 0.534 0.240 0.928
j2 0.298 0.538 0.522 0.195 0.911
j3 0.348 0.454 0.439 0.154 0.862
ja1 0.388 0.519 0.581 0.296 0.959
ja2 0.293 0.574 0.587 0.269 0.954
ja3 0.352 0.500 0.516 0.237 0.924
R 0.300 0.653 0.582 0.238 0.946
J 0.043 0.836 0.501 0.135 0.777
W 0.342 0.586 0.534 0.212 0.929
Te 0.401 0.506 0.625 0.317 0.970
Ee 0.341 0.538 0.585 0.288 0.955
Ne 0.335 0.541 0.580 0.285 0.953
SA 0.379 0.572 0.545 0.242 0.934
IP 0.050 0.337 0.106 0.073 0.036
LUMO 0.164 0.438 0.359 0.161 0.467
HOMO 0.050 0.337 0.106 0.073 0.036
l 0.084 0.571 0.323 0.071 0.356b. The high antimicrobial activity of compound 19 indi-
cated that the presence of electron withdrawing group
(2-chloro) on benzoyl portion and electron donating
group (4-isopropoxy) on benzamide portion increased
the antimicrobial activity of the synthesized isatin deriv-
atives. The role of electron releasing groups in enhancing
the antimicrobial activity of isatin derivatives is further
supported by the study of Pandeya et al. (1999).
c. The anticancer activity results indicated that the presence
of unsubstituted pyrimidine ring attached to benzenesul-
fonamide moiety (3) increased the anticancer potential of
the synthesized compounds against HCT116 cancer cell
lines.
d. The anticancer activity results also indicated that the
presence of electron releasing methoxy group on the
pyrimidine ring attached to benzene sulfonamide moiety
(16) improved the anticancer activity of synthesized
compounds against RAW 264.7 cancer cell lines which
indicated that this substitution is beneﬁcial for the bind-
ing with the receptor ANP. The role of electron releasing
groups in improving anticancer activity is supported by
the studies of Mologni et al. (2010).
e. From the above mentioned antimicrobial and anticancer
activity results, it can be concluded that different struc-
tural requirements are necessary for a compound to be
active against different microbial and cancer targets.
This is in accordance with the ﬁndings of Sortino et al.
(2007) and Yogeeswari et al. (2005).
The above ﬁndings are summarized in Fig. 1.
2.5. QSAR studies
In order to identify the substituent effect on the antimicrobial
activity, quantitative structure–activity relationship (QSAR)
studies were undertaken using the linear free energy relationship
model (LFER) described by Hansch and Fujita (1964)). Biolog-
ical activity data determined as MIC values were ﬁrst trans-
formed into pMIC values (i.e. log MIC) and used as a
dependent variable in the QSAR study. The different molecular
descriptors (independent variables) like log of octanol–water
partition coefﬁcient (log P), molar refractivity (MR), Kier’s
molecular connectivity (0v, 0vv, 1v, 1vv, 2v, 2vv) and shape (j1,
j2, j3, j1, j2, j3) topological indices, Randic topological index
(R), Balaban topological index (J), Wiener topological index
(W), Total energy (Te), energies of highest occupied molecular
orbital (HOMO) and lowest unoccupied molecular orbital
4-(1-Aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted benzene sulfonamides 441(LUMO), dipole moment (l), nuclear repulsion energy (Nu.E)
and electronic energy (Ele.E) were calculated for isatin deriva-
tives and values of selected descriptors are presented in Table 3
(Hansch et al., 1973; Kier and Hall, 1976; Randic, 1975, 1993;
Balaban, 1982; Wiener, 1947). Units of the energies and dipole
were electron volts (eV), and atomic units (a.u.), respectively
(Dai et al., 1999).
In the present study, a data set of 20 isatin derivatives was
subjected to linear free energy regression analysis for model
generation. During the regression analysis studies it was ob-
served that the response values of compounds 1, 3, 7, 11, 16
and 17 were outside the limits of response values of other syn-
thesized isatin derivatives. Thus compounds 1, 3, 7, 11, 16 and
17 were designated as outliers and were not involved in the data
set for QSAR model generation. In multivariate statistics, it is
common to deﬁne three types of outliers (Furusjo et al., 2006).
1. X/Y relation outliers are substances for which the relation-
ship between the descriptors (X variables) and the depen-
dent variables (Y variables) is not the same as in the (rest
of the) training data.
2. X outliers. Brieﬂy, a substance is an X outlier if the molec-
ular descriptors for this substance do not lie in the same
range as the (rest of the) training data.
3. Y outliers are only deﬁned for training or test samples.
They are substances for which the reference value of
response is invalid.
As there was no difference in the activity (Table 2) as well as
the molecular descriptor range (Table 3) of these outliers when
compared to other isatin derivatives, these outliers belong to
the category of Y outliers (Substances for which the reference
value of response is invalid).
Preliminary analysis was carried out in terms of correlation
analysis. A correlation matrix constructed for antifungal activ-
ity against A. niger is presented in Table 4. In general, high
colinearity (r> 0.5) was observed between different parame-
ters. The high interrelationship was observed between topolog-
ical parameter, Randic index (R) and steric parameter, molar
refractivity (MR, r= 0.991) and low interrelationship was ob-
served between electronic parameter, HOMO and topological
parameter, valance zero order molecular connectivity index
(0vv, r= -0.002). The correlations of different molecular
descriptors with antibacterial and antifungal activity against
different microorganisms are presented in Table 5.
The correlation matrix (Table 4) indicated the predomi-
nance of topological parameter, valance zero order molecular
connectivity index (0vv) in describing the antifungal activity
of the synthesized compounds against A. niger. Thus, QSAR
model for antifungal activity against A. niger was developed
using valance zero order molecular connectivity index (0vv).
pMICan ¼ 0:01740vv þ 1:571
n ¼ 14 r ¼ 0:980 q2 ¼ 0:945 s ¼ 0:0069 F ¼ 296:78
ð1Þ
Here and thereafter, n – number of data points, r – correlation
coefﬁcient, q2 – cross validated r2 obtained by leave one out
method, s – standard error of the estimate and F – Fischer
statistics.
Topological indices are numerical quantiﬁers of molecular
topology and are sensitive to bonding pattern, symmetry,content of heteroatom as well as degree of complexity of atomic
neighborhoods (Lather andMadan, 2005). The valence zero or-
der molecular connectivity topological index (0vv) represents
the molecules with branched structure. In this case, the positive
correlation was observed between 0vv and antifungal activity
against A. niger. Therefore, the antifungal activity of synthe-
sized compounds against A. niger will increase with increase
in their 0vv values. This is clearly evident from Table 3 that com-
pound 19 having highest 0vv value of 25.26 is having highest
antifungal activity against A. niger (pMICan = 2.01, Table 2).
The QSAR model expressed by Eq. (1) was cross validated
by its high q2 value (q2 = 0.945) obtained with leave one out
(LOO) method. The value of q2 greater than 0.5 is the basic
requirement for qualifying a QSAR model to be a valid one
(Golbraikh and Tropsha, 2002). The comparison of observed
and predicted antifungal activities is presented in Table 6. It
can be seen from the results that the observed and predicted
antifungal activities against A. niger lie close to each other as
evidenced by their low residual values Table 6. The plots of ob-
served, predicted and residual pMICan values were also devel-
oped to check the statistical validity of QSAR models. The
plot of predicted pMICan against observed pMICan (Fig. 2)
also favors the model expressed by Eq. (1). Further, the plot
of observed pMICan vs residual pMICan (Fig. 3) indicated that
there was no systemic error in model development as the prop-
agation of error was observed on both sides of zero (Kumar
et al., 2007).
Lipophilic parameter, log P was the most dominating
parameter in describing the antibacterial activity of the synthe-
sized compounds against B. subtilis and E. coli.
pMICbs ¼ 0:172 log pþ 1:058
n ¼ 14 r ¼ 0:859 q2 ¼ 0:657 s ¼ 0:089 F ¼ 33:78 ð2Þ
In order to improve the value of correlation coefﬁcient, we
coupled log P with dipole moment (l), which resulted in best
QSAR model for antibacterial activity of synthesized com-
pounds against B. subtilis (Eq. (3)).
pMICbs ¼ 0:150 log Pþ 0:195lþ 0:997
n ¼ 14 r ¼ 0:892 q2 ¼ 0:711 s ¼ 0:083 F ¼ 21:51 ð3Þ
As in case of antibacterial activity against B. subtilis, the
antibacterial activity of the synthesized compounds against E.
coli (Eq. (4)) was also positively correlated with log P. Hence,
antibacterial activity of synthesized compounds against both
bacterial strains will increase with increase in their log P values.
pMICec ¼ 0:128 log Pþ 1:297
n ¼ 14 r ¼ 0:721 q2 ¼ 0:331 s ¼ 0:108 F ¼ 12:98 ð4Þ
Antibacterial activity of synthesized compounds against S.
aureus was best described by topological parameter, valance
third order molecular connectivity index (3vv) which was pos-
itively correlated with antibacterial activity (Eq. (5)).
Progress in the use of quantitative structure–activity rela-
tionship (QSAR) methods has shown the importance of the
hydrophobic or lipophilic nature of biologically active mole-
cules. The lipophilicity modiﬁes the penetration of bioactive
molecules through the apolar cell membranes. This property
is usually characterized by the partition coefﬁcient (log P),
which is essentially determined from distribution studies of
the compound between an immiscible polar and non-polar sol-
vent pair.
Table 6 Comparison of observed and predicted antimicrobial activity obtained by mt-QSAR models.
Comp. pMICsa pMICbs pMICec pMICan
Obs. Pre. Res. Obs. Pre. Res. Obs. Pre. Res. Obs. Pre. Res.
1 1.62 1.76 0.14 1.62 1.82 0.20 1.62 1.85 0.23 1.92 1.93 0.01
2 1.89 1.80 0.09 1.59 1.64 0.05 1.59 1.70 0.11 1.89 1.90 0.01
3 1.92 1.63 0.29 1.92 1.80 0.12 1.62 1.82 0.20 1.92 1.92 0.00
4 1.93 1.75 0.18 1.93 1.82 0.11 1.63 1.85 0.22 1.93 1.94 0.01
5 1.62 1.73 0.11 1.92 1.87 0.05 1.92 1.90 0.02 1.92 1.92 0.00
6 1.67 1.72 0.05 1.67 1.85 0.18 1.97 1.88 0.09 1.97 1.97 0.00
7 1.94 1.66 0.28 1.94 1.73 0.21 1.94 1.87 0.07 1.94 1.94 0.00
8 1.62 1.65 0.03 1.92 1.85 0.07 1.92 1.87 0.05 1.92 1.92 0.00
9 1.98 1.95 0.03 1.98 1.98 0.00 1.98 2.01 0.03 1.98 1.99 0.01
10 1.59 1.73 0.14 1.59 1.55 0.04 1.59 1.71 0.12 1.89B 1.89 0.00
11 1.65 1.92 0.27 1.65 1.90 0.25 1.95 1.92 0.03 1.95 1.94 0.01
12 1.92 1.96 0.04 1.62 1.72 0.10 1.92 1.77 0.15 1.92 1.92 0.00
13 1.65 1.79 0.14 1.95 1.89 0.06 1.95 1.89 0.06 1.95 1.94 0.01
14 1.96 1.91 0.05 1.96 1.92 0.04 1.96 1.91 0.05 1.96 1.96 0.00
15 1.95 1.89 0.06 1.95 1.94 0.01 1.95 1.97 0.02 1.95 1.94 0.01
16 1.69 1.85 0.16 1.69 1.87 0.18 1.99 1.94 0.05 1.99 1.99 0.00
17 1.67 1.84 0.17 1.97 1.92 0.05 1.97 1.94 0.03 1.97 1.96 0.01
18 1.95 1.80 0.15 1.95 1.93 0.02 1.95 1.94 0.01 1.95 1.94 0.01
19 2.01 2.11 0.10 2.01 2.07 0.06 2.01 2.08 0.07 2.01 2.01 0.00
20 1.92 1.89 0.03 1.62 1.62 0.00 1.92 1.78 0.14 1.92 1.91 0.01
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Figure 2 Plot of observed pMICan against predicted pMICan
obtained by Eq. (1).
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Figure 3 Plot of observed pMICan against residual pMICan
obtained by Eq. (1).
442 M. Kumar et al.This quantitative descriptor of lipophilicity (logP) is one of the
keydeterminantsof pharmacokineticproperties.Knowing the ex-
act values for this parameter, it is possible to predict the inhibitory
activity of the drugs (Podunavac-Kuzmanovic et al., 2008).
log P is the logarithm of the ratio of the concentrations of
the un-ionized solute in two solvents, which is calculated
according to the following equation, where o is octanol and
w is un-ionized water.
log Po=w ¼ logð½soluteo=½solutewÞ
The hydrophobic effect is the major driving force for the bind-
ing of drugs to their receptor targets in pharmacodynamics,
and is based on the log P contribution of each atom. Each
atom in a molecule contributes to the log P by the amount
of its atomic parameter multiplied by the degree of exposure
to the surrounding solvent (Park et al., 2008)pMICsa ¼ 0:7683vv þ 0:582
n ¼ 14 r ¼ 0:760 q2 ¼ 0:272 s ¼ 0:118 F ¼ 11:91 ð5Þ
In order to improve the value of correlation coefﬁcient, we
coupled valance third order molecular connectivity index
(3vv) with Balaban index (J) which resulted in best QSAR
model for antibacterial activity of synthesized compounds
against S. aureus (Eq. (6)).
pMICsa ¼ 0:9343vv þ 0576J 0:356
n ¼ 14 r ¼ 0:769 q2 ¼ 0:342 s ¼ 0:111 F ¼ 7:95 ð6Þ
As in case of Eq. (1), the high q2 value (q2 = 0.711) supported
the validity of developed QSAR model for antibacterial activ-
ity against B. subtilis (Eq. (3)). In case of antibacterial activity
against E. coli (Eq. (4)) and S. aureus (Eq. (6)) the value q2 is
less than 0.5 (0.331 and 0.342, respectively), which shows that
4-(1-Aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted benzene sulfonamides 443the developed models are invalid ones. But according to the
recommendations of Kim et al. (2007), the regression models
are acceptable if the value of standard deviation (SD, Table 2)
is not much larger than 0.3. As the value of standard deviation
is less than 0.3 (Table 2), the developed QSAR models for anti-
bacterial activity against E. coli (Eq. (4)) and S. aureus (Eq.
(6)) are valid ones. Further, the low residual values (Table 6)
supported the validity of QSAR models i.e. Eqs. (4) and (6).
It is important to note that no signiﬁcant correlation was
observed between the antifungal activity of synthesized com-
pounds against C. albicans and their physicochemical parame-
ters. Further, high residual activity values observed in case of
outliers (compounds 1, 3, 7, 11, 16 and 17) justiﬁed their re-
moval before the development of QSAR models.
Generally for QSAR studies, the biological activities of
compounds should span 2–3 orders of magnitude. But in
the present study the range of antibacterial and antifungal
activities of the synthesized compounds is within one order
of magnitude. It is important to note that the predictability
of the QSAR models developed in the present study is high
evidenced by their low residual values. This is in accordance
with results suggested by the Bajaj et al. (2005), who stated
that the reliability of the QSAR model lies in its predictive
ability even though the activity data are in the narrow range.
Further, recent literature reveals that the QSAR models have
been applied to describe the relationship between narrow
range of biological activity and physicochemical properties
of the molecules (Narasimhan et al., 2007; Sharma et al.,
2006; Hatya et al., 2006; Kumar et al., 2006). When biological
activity data lie in the narrow range, the presence of minimum
standard deviation of the biological activity justiﬁes its use in
QSAR studies (Kumar et al., 2007; Narasimhan et al., 2007).
The minimum standard deviation (Table 2) observed in the
antimicrobial activity data justiﬁes its use in QSAR studies.
In summary, the antimicrobial activity of synthesized isatin
derivatives against different microbial strains was governed by
lipophilic parameter, log P and topological parameters valance
zero and third ordermolecular connectivity indices (0vv and 3vv).
3. Conclusion
A series of 4-(1-aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-ylide-
neamino)-N-substituted benzenesulfonamide derivatives (1–
20) was synthesized and evaluated for its in vitro antimicrobial
and anticancer activities. Antimicrobial study indicated that
compounds 9 and 19 were found to be the most effective anti-
microbial agents. Anticancer results indicate that all the syn-
thesized compounds were more potent than the standard
drug carboplastin but less active than the standard drug 5-ﬂu-
orouracil (5-FU) against both the cells (HCT116 and RAW
264.7). The compound 3 was found to be the most potent
one against HCT116 and compound 16 against RAW 264.7.
4. Experimental
4.1. Chemistry
Starting materials were obtained from commercial sources and
were used without further puriﬁcation. Solvents were dried by
standard procedures. Reaction progress was observed by thin
layer chromatography. Melting points were determined inopen capillary tubes on a Sonar melting point apparatus and
were uncorrected. 1H and 13C NMR spectra were determined
by Bruker 500 MHz NMR spectrometer in appropriate deuter-
ated solvents and are expressed in parts per million (d, ppm)
downﬁeld from tetramethylsilane (internal standard). NMR
data are given as multiplicity (s, singlet; d, doublet; t, triplet;
m, multiplet) and number of protons. IR spectra were recorded
on a Varian Resolutions Pro spectrophotometer in a KBr disk.
4.2. General procedure for the synthesis of 4-(1-aryl-5-chloro-2-
oxo-1, 2-dihydro-indol-3-ylideneamino)-N-substituted
benzenesulfonamide (1–20)
Thionyl chloride 32.8 g (0.3 mol) was added to different aro-
matic acids (0.25 mol) in a round bottomed ﬂask. After addi-
tion, the mixture was reﬂuxed for 2 h. The excess of thionyl
chloride was removed by distillation. To the solution of acid
chloride (1 mol) 0.1 mol of 5-chloroisatin was added and the
mixture was reﬂuxed for 1 h and 30 min. Then the reaction
mixture was cooled and the resultant precipitate (N-acyl 5-
chloroisatin) was collected, washed with hexane and recrystal-
lized from ethyl acetate. A solution of 0.05 mol of different sul-
fonamides in warm ethanol was added to the corresponding
solution of N-acyl 5-chloroisatin (0.05 mol) in the presence
of small amount of glacial acetic acid. The mixture was re-
ﬂuxed for 4–6 h. Then the reaction mixture was allowed to
cool at room temperature and the precipitate obtained was ﬁl-
tered, dried and recrystallized from ethanol.
4.2.1. 4-(1-benzoyl-5-chloro-2-oxoindolin-3-ylideneamino)-N-
(5-methylisoxazol-3-yl) benzenesulfonamide (1)
Mp (C) 246–248; Yield – 85%; IR (KBr pellets)cm1 1494
(NH in plane bending, sec. amine), 1681 (C‚O str., Ar–
C‚O), 1651 (C‚N str.), 1179 (O‚S‚O str.), 730 (C–Cl
str., Ar–Cl), 1247 (–C–O–N str., isoxazole), 894 (CH out of
plane bending, isoxazole), 894–699 (CH out of plane bending,
indole). 1H NMR (DMSO) d; 6.14–7.96 (12, m, ArH), 4.17
(1H, s, SO2NH), 2.30 (3H, s, ArCH3);
13CNMR (DMSOd6,
d ppm): 166.18, 161.62, 136.46, 133.62, 129.89, 129.30,
129.12, 128.06, 125.82.
4.2.2. N-(4-(1-benzoyl-5-chloro-2-oxoindolin-3-
ylideneamino)phenylsulfonyl)acetamide (2)
Mp (C) 88–90; Yield – 80%; IR (KBr pellets) cm1 1494 (NH
in plane bending, sec. amine), 1682 (C‚O str., Ar–C‚O),
1651 (C‚N str.), 1180 (O‚S‚O str.), 1494 (CH3 bending
vibration, COCH3), 730 (C–Cl str., Ar–Cl), 894–699 (CH out
of plane bending, indole). 1H NMR (DMSO) d; 7.58–7.97
(12H, m, ArH), 4.01 (1H, s, SO2NH), 2.38 (3H, s, COCH3).
4.2.3. 4-(1-benzoyl-5-chloro-2-oxoindolin-3-ylideneamino)-N-
(pyrimidin-2-yl) benzenesulfonamide (3)
Mp (C) 252–254; Yield – 72%; IR (KBr pellets) cm1 1493
(NH in plane bending, sec. amine), 1682 (C‚O str., Ar–
C‚O), 1651 (C‚N str.), 1180 (O‚S‚O str.), 1604 (C‚N
str., pyrimidine), 700 (C–Cl str., Ar–Cl), 730 (CH out of plane
bending, 4-sustituted pyrimidine), 894–657 (CH out of plane
bending, indole). 1H NMR (DMSO) d; 6.58–8.71 (15H, m,
ArH), 4.18 (1H, s, SO2NH);
13CNMR (DMSOd6, d ppm):
166.18, 161.63, 136.47, 133.64, 132.88, 129.91, 129.32, 129.13,
128.07, 128.83.
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(4-methylpyrimidin-2-yl) benzenesulfonamide (4)
Mp (C) 268–270; Yield – 76%; IR (KBr pellets) cm1 1493
(NH in plane bending, sec. amine), 1681 (C‚O str., Ar–
C‚O), 1651 (C‚N str.), 1180 (O‚S‚O str.), 1575 (C‚N
str., pyrimidine), 700 (C–Cl str., Ar–Cl), 752–795 (CH out of
plane bending, 4-sustituted pyrimidine), 897–697 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 6.58–8.71
(14H, m, ArH), 4.17 (1H, s, SO2NH), 2.33 (3H, s, ArCH3).
4.2.5. 4-(1-benzoyl-5-chloro-2-oxoindolin-3-ylideneamino)-N-
(thiazol-2-yl) benzene sulfonamide (5)
Mp (C) 213–215;Yield – 82%; IR (KBr pellets) cm1 1493 (NH
in plane bending, sec. amine), 1683 (C‚O str., Ar–C‚O), 1652
(C‚N str.), 1150 (O‚S‚O str.), 1576 (C = N str., thiazole),
731 (C–Cl str., Ar–Cl), 750 (C–S–C str., thiazole), 897 (CH
out of plane bending, thiazole), 897–699 (CH out of plane bend-
ing, indole). 1H NMR (DMSO) d; 6.55–7.95 (14, m, ArH), 4.15
(1H, s, SO2NH);
13CNMR (DMSOd6, d ppm): 166.34, 166.18,
161.65, 161.19, 141.49, 137.86, 136.64, 136.53, 133.67, 133.60,
132.87, 132.61, 130.57, 129.94, 129.21, 129.12, 128.91, 128.75,
128.06, 127.17, 125.80, 125.37, 124.89, 120.34, 108.64.
4.2.6. 4-(1-benzoyl-5-chloro-2-oxoindolin-3-ylideneamino)-N-
(4, 6-dimethoxypyrimidin-2-yl)benzenesulfonamide (6)
Mp (C) 124–126; Yield – 85%; IR (KBr pellets) cm1 1494
(NH in plane bending, sec. amine), 1684 (C‚O str., Ar–
C‚O), 1652 (C‚N str.), 1180 (O‚S‚O str.), 1286 (C–O–C
str.), 1576 (C‚N str., pyrimidine), 731 (C–Cl str., Ar–Cl),
1602 (C = C str., pyrimidine), 894–659 (CH out of plane
bending, indole).1H NMR (DMSO) d; 6.55–7.95 (13H, m,
ArH), 4.17 (1H, s, SO2NH), 3.65 (6H, s, ArOCH3).
4.2.7. 4-(1-benzoyl-5-chloro-2-oxoindolin-3-ylideneamino)-N-
(6-methoxypyridazin-3-yl) benzenesulfonamide (7)
Mp (C) 208–210; Yield – 74%; IR (KBr pellets)cm1 1493
(NH in plane bending, sec. amine), 1681 (C‚O str., Ar–
C‚O), 1652 (C‚N str.), 1183 (O‚S‚O str.), 1287 (C–O–C
str.), 1400 (N–N str., pyridazine), 730 (C–Cl str., Ar–Cl),
887–656 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 6.56–8.74 (14H, m, ArH), 4.19 (1H, s, SO2NH), 3.33 (3H, s,
ArOCH3);
13CNMR (DMSOd6, d ppm):166.17, 161.65,
149.23, 141.01, 136.53, 133.67, 132.87, 129.94, 129.12, 128.93,
128.06, 125.80, 125.33, 120.43, 101.62.
4.2.8. 4-(1-benzoyl-5-chloro-2-oxoindolin-3-ylideneamino)-N-
(pyridin-2-yl) benzene sulfonamide (8)
Mp (C) 220–222;Yield – 68%; IR (KBr pellets) cm1 1495 (NH
in plane bending, sec. amine), 1683 (C = O str., Ar–C = O),
1651 (C = N str.), 1182 (O = S= O str.), 1577 (C = N str.,
pyridine), 1602 (C = C str., pyridine), 731 (C–Cl str., Ar–Cl),
895–617 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 6.55–8.11 (16H, m, ArH), 4.19 (1H, s, SO2NH).
4.2.9. N-(4-(1-benzoyl-5-chloro-2-oxoindolin-3-ylideneamino)
phenylsulfonyl)-4-iso propoxybenzamide (9)
Mp (C) 208–210; Yield – 74%; IR (KBr pellets) cm1 1515
(NH in plane bending, sec. amine), 1684 (C‚O str., Ar–
C‚O), 1653 (C‚N str.), 1182 (O‚S‚O str.), 1166(CH(CH3)2 bending), 1259 (C–O–C str.), 732 (C–Cl str.,
Ar–Cl), 886–645 (CH out of plane bending, indole). 1H
NMR (DMSO) d; 6.09–7.95 (16H, m, ArH), 4.72 (1H, s,
SO2NH), 4.19 (1H, s, CH), 1.29 (6H, d, CH(CH3)2);
13CNMR (DMSOd6, d ppm): 166.19, 164.75, 161.72,
161.66, 154.04, 136.52, 133.67, 133.61, 132.88, 130.92,
130.46, 129.94, 129.25, 128.07, 125.82, 124.55, 123.98,
115.42, 112.68.4.2.10. 1-(4-(1-benzoyl-5-chloro-2-oxoindolin-3-
ylideneamino)phenylsulfonyl)guanidine (10)
Mp (C) 88–90; Yield – 80%; IR (KBr pellets) cm1 1516 (NH
in plane bending, sec. amine), 1681 (C‚O str., Ar–C‚O),
1650 (C‚N str.), 1181 (O‚S‚O str.), 699 (C–Cl str., Ar–
Cl), 898–641 (CH out of plane bending, indole). 1H NMR
(DMSO) d; 7.46–7.95 (12H, m, ArH), 4.20 (1H, s, SO2NH),
3.31 (3H, s, COCH3).4.2.11. 4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)-N-(5-methyl isoxazol-3-yl)benzenesulfonamide
(11)
Mp (C) 203–205; Yield – 76%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1656 (C‚N str.), 1142 (O‚S‚O str.), 777 (C–Cl
str., Ar–Cl), 895 (CH out of plane bending, isoxazole), 895–
665 (CH out of plane bending, indole). 1H NMR (DMSO) d;
7.47–8.06 (12H, m, ArH), 4.17 (1H, s, SO2NH), 2.38 (3H, s,
ArCH3).4.2.12. N-(4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)phenyl sulfonyl)acetamide (12)
Mp (C) 220–222; Yield – 76.87%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1686 (C‚O str., Ar–
C‚O), 1655 (C‚N str.), 1183 (O‚S‚O str.), 777 (C–Cl
str., Ar–Cl), 1402 (CH3 bending vibration, COCH3), 895–665
(CH out of plane bending, indole). 1H NMR (DMSO) d;
7.58–7.97 (14H, m, ArH), 4.18 (1H, s, SO2NH), 2.37 (3H, s,
COCH3);
13CNMR (DMSOd6, d ppm): 165.17, 161.57,
137.74, 136.15, 133.59, 132.33, 130.01, 129.86, 129.63, 129.37,
129.24, 126.01.
4.2.13. 4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)-N-(pyrimidin-2-yl) benzenesulfonamide (13)
Mp (C) 220–222; Yield – 76.87%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1656 (C‚N str.), 1183 (O‚S‚O str.), 777 (C–Cl
str., Ar–Cl), 1593 (C‚N str., pyrimidine), 777 (CH out of
plane bending, 4-sustituted pyrimidine), 896–665 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 7.65–7.97
(14H, m, ArH), 4.18 (1H, s, SO2NH).
4.2.14. 4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)-N-(4-methyl pyrimidin-2-yl)benzenesulfonamide
(14)
Mp (C) 220–222; Yield – 76.87%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1686 (C‚O str., Ar–
C‚O), 1656 (C‚N str.), 1183 (O‚S‚O str.), 777 (C–Cl
str., Ar–Cl), 1593 (C‚N str., pyrimidine), 777 (CH out of
4-(1-Aryl-5-chloro-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted benzene sulfonamides 445plane bending, 4-sustituted pyrimidine), 896–666 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 7.58–8.02
(13H, m, ArH), 4.19 (1H, s, SO2NH), 2.38 (3H, s, ArCH3);
13CNMR (DMSOd6, d ppm): 165.17, 161.56, 137.74, 136.14,
133.58, 132.33, 130.01, 129.85, 129.65, 129.37, 129.24, 126.02.
4.2.15. 4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)-N-(thiazol-2-yl) benzenesulfonamide (15)
Mp (C) 220–222; Yield – 76.87%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1655 (C‚N str.), 1183 (O‚S‚O str.), 777 (C–Cl
str., Ar–Cl), 1593 (C‚N str., thiazole), 739 (C–S–C str., thia-
zole), 896–666 (CH out of plane bending, indole, thiazole). 1H
NMR (DMSO) d; 7.64–7.96 (13, m, ArH), 4.18 (1H, s,
SO2NH).
4.2.16. 4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)-N-(4,6-dimethoxy pyrimidin-2-
yl)benzenesulfonamide (16)
Mp (C) 220–222; Yield – 76.87%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1686 (C‚O str., Ar–
C‚O), 1656 (C‚N str.), 1183 (O‚S‚O str.), 777 (C–Cl
str., Ar–Cl), 1250 (C–OC str.), 1594 (C‚N str., pyrimidine),
896–666 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 7.51–8.06 (12H, m, ArH), 4.19 (1H, s, SO2NH), 3.30 (6H, s,
ArOCH3).
4.2.17. 4-(5-chloro-1-(4-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)-N-(6-methoxy pyridazin-3-
yl)benzenesulfonamide (17)
Mp (C) 220–222; Yield – 76.87%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1655 (C‚N str.), 1183 (O‚S‚O str.), 1250 (C–O–C
str.), 1402 (N–N str., pyridazine), 777 (C–Cl str., Ar–Cl),
896–666 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 7.51–8.03 (13H, m, ArH), 4.19 (1H, s, SO2NH), 3.31 (3H, s,
ArOCH3).
4.2.18. 4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)-N-(pyridin-2-yl) benzenesulfonamide (18)
Mp (C) 220–222; Yield – 76.87%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1655 (C‚N str.), 1183 (O‚S‚O str.), 777 (C–Cl
str., Ar–Cl), 1593 (C‚N str., pyridine), 896–665 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 7.51–8.02
(15H, m, ArH), 4.18 (1H, s, SO2NH);
13CNMR (DMSOd6, d
ppm): 165.18, 161.58, 137.75, 136.16, 133.60, 132.34, 130.02,
129.88, 129.61, 129.38, 129.24, 126.01, 112.87.
4.2.19. N-(4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino)phenyl sulfonyl)-4-isopropoxybenzamide (19)
Mp (C) 208–210; Yield – 74%; IR (KBr pellets) cm1 1492
(NH in plane bending, sec. amine), 1688 (C‚O str., Ar–
C‚O), 1656 (C‚N str.), 1186 (O‚S‚O str.), 1160
(CH(CH3)2 bending), 1259 (C–O–C str.), 742 (C–Cl str., Ar–
Cl), 889–668 (CH out of plane bending, indole). 1H NMR
(DMSO) d; 6.08–8.01 (15H, m, ArH), 4.76 (1H, s, SO2NH),
4.18 (1H, s, CH), 1.30 (6H, d, CH(CH3)2);
13CNMR
(DMSOd6, d ppm): 165.18, 164.75, 161.71, 161.59, 154.04,137.77, 136.18, 133.61, 132.34, 130.92, 130.46, 130.02, 129.89,
129.59, 129.39, 129.25, 126.00, 124.55, 123.98, 115.41, 112.61.
4.2.20. 1-(4-(5-chloro-1-(2-chlorobenzoyl)-2-oxoindolin-3-
ylideneamino) phenyl sulfonyl)guanidine (20)
Mp (C) 88–90; Yield – 80%; IR (KBr pellets) cm1 1491 (NH
in plane bending, sec. amine), 1688 (C‚O str., Ar–C‚O),
1656 (C‚N str.), 1186 (O‚S‚O str.), 741 (C–Cl str., Ar–
Cl), 896–666 (CH out of plane bending, indole). 1H NMR
(DMSO) d; 6.71–8.62 (11H, m, ArH), 4.19 (1H, s, SO2NH),
3.30 (3H, s, COCH3);
13CNMR (DMSOd6, d ppm): 165.17,
161.56, 137.74, 136.13, 133.58, 132.33, 130.02, 129.85, 129.67,
129.38, 129.24, 126.03.
4.3. Evaluation of antimicrobial activity
4.3.1. Determination of MIC
The antimicrobial activity was performed against Gram-posi-
tive bacteria: Staphylococcus aureus, B. subtilis, the Gram-neg-
ative bacterium E. coli and several fungal strains: C. albicans
and A. niger using the tube dilution method (Cappucino and
Sherman, 1999). Dilutions of test and standard compounds
were prepared in double strength nutrient broth – I.P. (bacte-
ria) or Sabouraud dextrose broth – I.P. (fungi) (Pharmaco-
poeia of India, 2007). The samples were incubated at 37 C
for 24 h (bacteria), at 25 C for 7 d (A. niger) and at 37 C
for 48 h (C. albicans) and the results were recorded in terms
of minimum inhibitory concentration (MIC).
4.3.2. Determination of MBC/MFC
The minimum bactericidal concentration (MBC) and fungi-
cidal concentration (MFC) were determined by sub culturing
100 lL of culture from each tube (which remained clear in
the MIC determination) on fresh medium. MBC and MFC
values represent the lowest concentration of compound that
produces a 99.9% end point reduction (Rodriguez-Arguelles
et al., 2005).
4.4. Anticancer evaluation
The anticancer activity of the synthesized compounds was
determined against murine leukemia (RAW 264.7) and colon
cancer (HCT116) cell lines. Cancer cell lines were purchased
from the American Type Culture Collection (ATCC),
Manassas, VA, USA. All cell lines were cultured in RPMI
1640 (Sigma) supplemented with 10% heat inactivated fetal
bovine serum (FBS) (PAA Laboratories) and 1% penicillin/
streptomycin (PAA Laboratories). Cultures were maintained
in a humidiﬁed incubator at 37 C in an atmosphere of 5%
CO2. Anticancer activity of the synthesized compounds at var-
ious concentrations was assessed using the 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma)
assay, as described by Mosmann (1983) but with minor mod-
iﬁcation, following 72 h of incubation. Assay plates were read
using a spectrophotometer at 520 nm. Data generated were
used to plot a dose–response curve of which the concentration
of test compounds required to kill 50% of the cell population
(IC50) was determined. Anticancer activity was expressed as
the mean IC50 of three independent experiments.
446 M. Kumar et al.4.5. QSAR studies
The structures of synthesized isatin derivatives were ﬁrst pre-
optimized with the Molecular Mechanics Force Field
(MM+) procedure included in Hyperchem 6.0 (1993) and the
resulting geometries were further reﬁned by means of the semi-
empirical method PM3 (Parametric Method-3). We chose a
gradient norm limit of 0.01 kcal/A˚ for the geometry optimiza-
tion. The lowest energy structure was used for each molecule
to calculate physicochemical properties using TSAR 3.3 soft-
ware for Windows (TSAR 3D Version 3.3, 2000). Further,
the regression analysis was performed using the SPSS software
package (SPSS for Windows, 1999).Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.arabjc.
2013.03.002.
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